These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 16703224)

  • 1. Circulating endothelial cells in venous blood as a marker of endothelial damage in chronic venous insufficiency: improvement with venoruton.
    Cesarone MR; Belcaro G; Pellegrini L; Ledda A; Vinciguerra G; Ricci A; Gizzi G; Ippolito E; Fano F; Dugall M; Acerbi G; Cacchio M; Di Renzo A; Hosoi M; Stuard S; Corsi M
    J Cardiovasc Pharmacol Ther; 2006 Mar; 11(1):93-8. PubMed ID: 16703224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HR (Venoruton1000, Paroven, 0-[beta-hydroxyethyl]-rutosides) vs. Daflon 500 in chronic venous disease and microangiopathy: an independent prospective, controlled, randomized trial.
    Belcaro G; Cesarone MR; Bavera P; Ricci A; Renton S; Leon M; Ippolito E; Dugall M; Acerbi G
    J Cardiovasc Pharmacol Ther; 2002 Jul; 7(3):139-45. PubMed ID: 12232562
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HR, 0-(beta-hydroxyethyl)-rutosides; (Venoruton): rapid relief of signs/symptoms in chronic venous insufficiency and microangiopathy: a prospective, controlled study.
    Cesarone MR; Belcaro G; Pellegrini L; Ledda A; Vinciguerra G; Ricci A; Gizzi G; Ippolito E; Fano F; Dugall M; Acerbi G; Cacchio M; Di Renzo A; Stuard S; Corsi M
    Angiology; 2005; 56(2):165-72. PubMed ID: 15793606
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Venoruton®: post thrombotic syndrome. Clinical improvement in venous insufficiency (signs and symptoms) with Venoruton®. A five-year, open-registry, efficacy study.
    Ippolito E; Belcaro G; Dugall M; Cesarone MR; Feragalli B; Errichi BM; Gizzi G; Pellegrini L; Ledda A; Luzzi R; Ricci A; Bavera P; Hosoi M; Corsi M; Errichi S
    Panminerva Med; 2011 Sep; 53(3 Suppl 1):13-9. PubMed ID: 22108472
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Investigation of the efficacy of oxerutins compared to placebo in patients with chronic venous insufficiency treated with compression stockings.
    Unkauf M; Rehn D; Klinger J; de la Motte S; Grossmann K
    Arzneimittelforschung; 1996 May; 46(5):478-82. PubMed ID: 8737630
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Venoruton vs Daflon: evaluation of effects on quality of life in chronic venous insufficiency.
    Cesarone MR; Belcaro G; Pellegrini L; Ledda A; Vinciguerra G; Ricci A; Di Renzo A; Ruffini I; Gizzi G; Ippolito E; Fano F; Dugall M; Acerbi G; Cornelli U; Hosoi M; Cacchio M
    Angiology; 2006; 57(2):131-8. PubMed ID: 16518519
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical improvement in chronic venous insufficiency signs and symptoms with Venoruton® (HR): an 8-month, open-registry, cost-efficacy study.
    Cesarone MR; Belcaro G; Ippolito E; Pellegrini L; Ledda A; Luzzi R; Ricci A; Dugall M; Bavera P; Hosoi M; Stuard S; Corsi M
    Panminerva Med; 2010 Jun; 52(2 Suppl 1):43-8. PubMed ID: 20657534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Variations in plasma free radicals in patients with venous hypertension with HR (Paroven, Venoruton; 0-(beta-hydroxyethyl)-rutosides): a clinical, prospective, placebo-controlled, randomized trial.
    Cesarone MR; Incandela L; DeSanctis MT; Belcaro G; Dugall M; Acerbi G
    J Cardiovasc Pharmacol Ther; 2002 Jan; 7 Suppl 1():S25-8. PubMed ID: 12011970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The LONFLIT4-Venoruton Study: a randomized trial--prophylaxis of flight-edema in venous patients.
    Cesarone MR; Belcaro G; Brandolini R; Di Renzo A; Bavera P; Dugall M; Simeone E; Acerbi G; Ippolito E; Winford M; Candiani C; Golden G; Ricci A; Stuard S
    Angiology; 2003; 54(2):137-42. PubMed ID: 12678187
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative clinical efficacy and tolerability of oxerutins and horse chestnut extract in patients with chronic venous insufficiency.
    Rehn D; Unkauf M; Klein P; Jost V; Lücker PW
    Arzneimittelforschung; 1996 May; 46(5):483-7. PubMed ID: 8737631
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oxerutins (Venoruton): efficacy in chronic venous insufficiency--a double-blind, randomized, controlled study.
    Petruzzellis V; Troccoli T; Candiani C; Guarisco R; Lospalluti M; Belcaro G; Dugall M
    Angiology; 2002; 53(3):257-63. PubMed ID: 12025912
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigation of the therapeutic equivalence of different galenical preparations of O-(beta-hydroxyethyl)-rutosides following multiple dose peroral administration.
    Rehn D; Brunnauer H; Diebschlag W; Lehmacher W
    Arzneimittelforschung; 1996 May; 46(5):488-92. PubMed ID: 8737632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. O-(beta-hydroxyethyl)-rutosides systemic and local treatment in chronic venous disease and microangiopathy: an independent prospective comparative study.
    Belcaro G; Rosaria Cesarone M; Ledda A; Cacchio M; Ruffini I; Ricci A; Ippolito E; Di Renzo A; Dugall M; Corsi M; Marino Santarelli AR; Grossi MG
    Angiology; 2008; 59 Suppl 1():7S-13S. PubMed ID: 18287162
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HR, 0-(beta-hydroxyethyl)-rutosides, in comparison with diosmin+hesperidin in chronic venous insufficiency and venous microangiopathy: an independent, prospective, comparative registry study.
    Cesarone MR; Belcaro G; Pellegrini L; Ledda A; Di Renzo A; Vinciguerra G; Ricci A; Gizzi G; Ippolito E; Fano F; Dugall M; Acerbi G; Cacchio M
    Angiology; 2005; 56(1):1-8. PubMed ID: 15678250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [New aspects in the pathogenesis of chronic venous insufficiency and the place of localized action of Venoruton].
    Bekers S; Zilstra I
    Akush Ginekol (Sofiia); 2002; 41 Suppl 2():28-32. PubMed ID: 19705689
    [No Abstract]   [Full Text] [Related]  

  • 16. HR (Paroven, Venoruton; 0-(beta-hydroxyethyl)-rutosides) in venous hypertensive microangiopathy: a prospective, placebo-controlled, randomized trial.
    Incandela L; Belcaro G; Renton S; DeSanctis MT; Cesarone MR; Bavera P; Ippolito E; Bucci M; Griffin M; Geroulakos G; Dugall M; Golden G; Acerbi G
    J Cardiovasc Pharmacol Ther; 2002 Jan; 7 Suppl 1():S7-S10. PubMed ID: 12011966
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effect of 0-(beta-hydroxyethyl)-rutoside (Venoruton) on symptomatic venous insufficiency in the lower limbs].
    Pedersen FM; Hamberg O; Sørensen MD; Neland K
    Ugeskr Laeger; 1992 Sep; 154(38):2561-3. PubMed ID: 1413183
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 5-Year control and treatment of edema and increased capillary filtration in venous hypertension and diabetic microangiopathy using O-(beta-hydroxyethyl)-rutosides: a prospective comparative clinical registry.
    Belcaro G; Cesarone MR; Ledda A; Cacchio M; Ruffini I; Ricci A; Ippolito E; Di Renzo A; Dugall M; Corsi M; Marino Santarelli AR; Grossi MG
    Angiology; 2008; 59 Suppl 1():14S-20S. PubMed ID: 18287163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of edema and increased capillary filtration in venous hypertension with HR (Paroven, Venoruton; 0-(beta-hydroxyethyl)-rutosides): a clinical, prospective, placebo-controlled, randomized, dose-ranging trial.
    Cesarone MR; Incandela L; DeSanctis MT; Belcaro G; Griffin M; Ippolito E; Acerbi G
    J Cardiovasc Pharmacol Ther; 2002 Jan; 7 Suppl 1():S21-4. PubMed ID: 12011969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the microcirculatory effects of Venoruton in patients with chronic venous hypertension by laserdoppler flowmetry, transcutaneous PO2 and PCO2 measurements, leg volumetry and ambulatory venous pressure measurements.
    Belcaro G; Rulo A; Candiani C
    Vasa; 1989; 18(2):146-51. PubMed ID: 2662674
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.